Trillium Therapeutics Inc (TRIL)

[NY1972]

PC and immune therapies

there are pathologic changes from the classic prostate adenocarcinoma to a neuroendocrine or anaplastic PC, a phenotype with little or no dependence on the androgen receptor pathway.
visceral disease scenario several cytokines mediate systemic immunosuppression. Immune treatments in this setting may be unable to counteract the established cancer-related immune system dysregulation. Timing of immune therapies may play a key role for treatment efficacy.

- See more at: http://www.cancernetwork.com/oncology-journal/visceral-metastases-prostate-cancer-underestimated-and-understudied-subgroup#sthash.ibE0Sh2l.dpuf